<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00502281</url>
  </required_header>
  <id_info>
    <org_study_id>05/2006e</org_study_id>
    <nct_id>NCT00502281</nct_id>
  </id_info>
  <brief_title>Controlled Ovarian Stimulation Followed by Timed Intercourse or Intrauterine Insemination in Infertile PCOS Patients</brief_title>
  <official_title>Timed Intercourse Versus Intrauterine Insemination in Infertile Patients Undergoing Gonadotropin Ovarian Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Magna Graecia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Magna Graecia</source>
  <brief_summary>
    <textblock>
      At the present the first options to induce ovulation in polycystic ovary syndrome with
      anovulatory infertility are clomiphene citrate (CC) and metformin. Notwithstanding the
      effectiveness of CC and metformin alone or in a sequential or combined regimen, a percentage
      of patients ranging from 5% to 30% remain anovulatory. For these patients, the use of
      gonadotropins for controlled ovarian stimulation (COS) is indicated.

      Moreover, to date it isn't clear if COS should be followed by timed intercourse (TI) or
      intrauterine insemination (IUI).

      The aim of the present study will be to compare TI and IUI in infertile PCOS patients
      undergoing COS in terms of cost-benefit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infertile PCOS patients who remain anovulatory after CC or metformin treatment will be
      enrolled. All patients will receive gonadotropins in low-dose step-up protocol for COS, and
      randomized to receive three trials of TI (group A) or IUI (group B).

      All patients eligible will undergo baseline assessment consisting of anthropometric,
      hormonal, and ultrasonographic evaluations.

      In all patients the COS will be obtained using highly purified urinary FSH in a low-dose
      step-up protocol, and both TI and IUI will be performed after 35 hours from ovulation
      induction with human chorionic gonadotropin.

      During the study, the clinical and reproductive outcomes, the adverse experience will be
      evaluated in each patient.

      Data will be analyzed using the intention-to-treat principle and a P value of 0.05 or less
      will be considered significant. Continuous variables will be analyzed with the unpaired t
      test and general linear model for repeated measures analysis with Bonferroni test for the
      post-hoc analysis as required. For categorical variables, the Pearson chi-square and Fisher's
      exact tests will be used. Cumulative pregnancy rate, our primary end-point, will be
      calculated by the Kaplan-Maier method, and the differences between the two groups will be
      assessed with the log-rank test. Cox proportional-hazards model will be used to calculate the
      hazard ratio for new pregnancy in both groups.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date>January 2007</start_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abortion rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OHSS</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple pregnancy rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COS followed by TI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>COS followed by IUI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>highly purified urinary FSH</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>timed intercourses, intrauterine insemination</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Polycystic ovary syndrome (using NIH criteria)

          -  Anovulatory infertility (using WHO criteria)

        Exclusion Criteria:

          -  Age &lt;18 or &gt;35 years

          -  Severe obesity (BMI &gt;35)

          -  Neoplastic, metabolic, hepatic, and cardiovascular disorders or other concurrent
             medical illnesses

          -  Hypothyroidism, hyperprolactinemia, Cushing's syndrome, and non-classical congenital
             adrenal hyperplasia

          -  Current or previous (within the last six months) use of oral contraceptives,
             glucocorticoids, antiandrogens, anti-obesity drugs, hormonal drugs

          -  Intention to start a diet or a specific program of physical activity

          -  Organic pelvic diseases

          -  Previous pelvic surgery

          -  Suspected peritoneal factor infertility

          -  Tubal or male factor infertility or sub-fertility
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Palomba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics &amp; Gynecology, University &quot;Magna Graecia&quot; of Catanzaro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Orio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology, University &quot;Federico II&quot; of Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Achille Tolino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics &amp; Gynecology, University &quot;Federico II&quot; of Naples</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pugliese Hospital</name>
      <address>
        <city>Catanzaro</city>
        <state>Catanzaro, CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2007</study_first_submitted>
  <study_first_submitted_qc>July 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2007</study_first_posted>
  <last_update_submitted>April 5, 2013</last_update_submitted>
  <last_update_submitted_qc>April 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Magna Graecia</investigator_affiliation>
    <investigator_full_name>Stefano Palomba</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Gonadotropins</keyword>
  <keyword>Infertility</keyword>
  <keyword>Intrauterine insemination</keyword>
  <keyword>PCOS</keyword>
  <keyword>Timed intercourse</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

